AUA Annual Meeting

Felix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.

"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."

The efficacy of radium-223 was not impacted by prior treatment with an androgen receptor inhibitor for men with bone metastatic castration-resistant prostate cancer.

Christopher Filson, MD, urology, UCLA Medical Center, discusses a study that used a MR-US fusion biopsy in 1000 men as a method to diagnose high-grade prostate cancer.

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses screening for prostate cancer.

Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.

Enzalutamide significantly improved progression-free survival and PSA progression compared with bicalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer.